SEC Form 4 · accession 0001209191-17-024799
Cidara Therapeutics, Inc. · CDTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey Stein
Officer — President & CEO · Director
Period of report
Mar 31, 2017
Accepted (ET)
Apr 4, 2017 · 4:33 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001610618
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Mar 31, 2017 | P | 12,900 | $7.75 | A | 27,196 | D | |
| Common Stock | holding | — | — | — | 203,697 | I | By trust | |
| Common StockF3 | holding | — | — | — | 420 | I | By son |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F4 | $7.80 | Mar 31, 2017 | A | 220,000 | A | — | Mar 30, 2027 | Common Stock | 220,000 | 220,000 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.50 to $7.875, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
- F2Includes 2,196 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on November 18, 2016.
- F3This holding, which was previously reported, was inadvertently omitted from the November 24, 2015 and May 20, 2016 Form 4 filings.
- F4The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 31, 2017.